nVerses Capital LLC Acquires 1,500 Shares of Merus (NASDAQ:MRUS)

nVerses Capital LLC lifted its holdings in shares of Merus (NASDAQ:MRUS) by 750.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,700 shares of the biotechnology company’s stock after purchasing an additional 1,500 shares during the quarter. nVerses Capital LLC’s holdings in Merus were worth $85,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in MRUS. California State Teachers Retirement System increased its stake in Merus by 2.9% in the first quarter. California State Teachers Retirement System now owns 33,745 shares of the biotechnology company’s stock valued at $1,520,000 after acquiring an additional 936 shares during the last quarter. Swiss National Bank increased its stake in Merus by 1.9% in the first quarter. Swiss National Bank now owns 74,054 shares of the biotechnology company’s stock valued at $3,335,000 after acquiring an additional 1,400 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Merus in the first quarter valued at approximately $72,000. SG Americas Securities LLC bought a new position in Merus in the first quarter valued at approximately $108,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Merus by 41.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,847 shares of the biotechnology company’s stock valued at $523,000 after acquiring an additional 2,572 shares during the last quarter. 96.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on MRUS shares. Bank of America reissued a “buy” rating and issued a $76.00 price objective on shares of Merus in a research note on Tuesday, June 25th. Canaccord Genuity Group restated a “buy” rating and issued a $67.00 target price on shares of Merus in a research report on Thursday, July 25th. Citigroup raised their target price on shares of Merus from $70.00 to $93.00 and gave the company a “buy” rating in a research report on Wednesday, June 26th. Guggenheim raised their target price on shares of Merus from $93.00 to $111.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Finally, Needham & Company LLC cut their target price on shares of Merus from $92.00 to $85.00 and set a “buy” rating on the stock in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $82.00.

Merus Stock Performance

Shares of NASDAQ:MRUS opened at $52.69 on Monday. The firm has a market cap of $3.09 billion, a PE ratio of -19.02 and a beta of 1.11. The firm’s fifty day moving average is $50.99 and its 200-day moving average is $50.71. Merus has a 52 week low of $19.81 and a 52 week high of $61.61.

Merus (NASDAQ:MRUS) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.05). Merus had a negative return on equity of 36.33% and a negative net margin of 476.41%. The firm had revenue of $7.33 million for the quarter, compared to the consensus estimate of $9.64 million. Sell-side analysts forecast that Merus will post -3.27 EPS for the current year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.